Prostate cancer lesions are surrounded by FOXP3⁺, PD-1⁺ and B7-H1⁺ lymphocyte clusters

Abstract

The immune response against prostate cancer seems to be inefficient although tumour cells show an over-expression of tumour-associated antigens suggesting that regulatory networks inhibit immune cell function locally. To address this proposition, lymphocytes within prostate cancer-inflicted tissue were analysed for the expression of markers associated with negative regulatory function and exhaustion.

Prostate cancer, benign prostatic hyperplasia and healthy prostate tissues were investigated by immunohistology for CD25, FOXP3, PD-1 and B7-H1.

We had previously documented that prostate cancer islets are surrounded by clustered accumulations of CD3⁺ lymphocytes, which lack perforin and interferon-gamma (IFNγ) expression, thus are apparently quiescent. Here, we report that these clusters contain numerous CD25⁺ and FOXP3⁺ cells. These markers are associated with regulatory T cells, and their presence in lymphocyte clusters near prostate cancer regions indicates an environment with negative impact on immune response against cancer cells. Consistent with this hypothesis, cells expressing PD-1 and its ligand B7-H1, which are markers associated with exhaustion of lymphocyte function, were also detected in the lymphocyte clusters.

Expression of molecules associated with inhibition and exhaustion of lymphocytes may reflect events contributing to ineffective immune responses against cancer cells.

Introduction

Prostate cancer is the most common solid-organ cancer of men in Western countries and follows lung cancer as the second most frequent cancer-related cause of death. Among all malignant urological tumours, prostate cancer is the leading cause of death.1, 2 Despite its high incidence, the prognosis for patients with prostate cancer is excellent when the carcinoma is detected at a stage when curative treatments, like prostatectomy or radiation therapy, can be implemented.

Prostate cancer cells express several tumour-associated antigens, like PSMA. Nevertheless, the immune response against prostate cancer is inefficient. Investigating tumour-infiltrating lymphocytes is an important strategy to improve our understanding about immunological events that occur in the tumour environment. Infiltration of lymphocytes has been described for a number of solid tumours.3, 4 The infiltration of lymphocytes into the tumour microenvironment seems to play a role in anti-tumour immunity.⁵ Furthermore, infiltrating lymphocytes have been associated with prognosis in some cancer patients. In colorectal cancer, for instance, a low density of CD3⁺ infiltrating lymphocytes was associated with reduced survival time compared to patients with a high density of CD3⁺ infiltrating lymphocytes.⁶ Despite the presence of infiltrating lymphocytes, the question remains why efficient tumour cell elimination does not occur.

CD4⁺ CD25⁺ T cells are consistently observed among the total CD4⁺ lymphocyte population in mice and humans. These cells have been associated with regulatory activity in immune responses in both species. The leading function of regulatory T cells (Tregs) is to control immune recognition to self-antigens, thereby preventing autoimmunity.7, 8 Tregs have also been seen in human cancers. Nevertheless, their role in cancer pathogenesis is not yet clarified, and has become a central focus of research during the past several years.9, 10

A second form of immune suppression can be mediated by the PD-1-receptor and its ligand B7-H1.¹¹ The presence of PD-1 or B7-H1 was associated with disease progression in chronic viral infections in mice and in HIV-infected individuals.12, 13 Moreover, PD-1-deficient mice developed autoimmune diseases.¹⁴ Thus, the expression of PD-1 and B7-H1 plays an important role in immune regulation.

In this study, freshly resected prostate carcinoma tissues, benign prostatic hyperplasia (BPH) and healthy prostate gland tissues were analysed for the presence of regulatory T lymphocyte markers using antibodies CD25 and FOXP3, as well as PD-1 and B7-H1.

We had previously described a clustered accumulation of CD3⁺ and CD4⁺ lymphocytes around prostate cancer islets with only few lymphocytes scattered within the tumour area. The lymphocytes were predominantly negative for perforin and IFNγ suggesting that they were functionally inactive.¹⁵ Now, we report that CD25⁺ and FOXP3⁺ cells are abundantly present within these lymphocyte clusters. Additionally, we document the presence of PD-1⁺ and B7-H1⁺ cells within the lymphocyte clusters. The presence of cells with negative immune regulatory activity and functionally exhausted cells may in part explain the previously observed quiescent lymphocyte phenotype. These findings together provide novel insight and a more detailed understanding of the in situ immune regulation to prostate cancer.